Skip to main content

[M24-977] A Phase 2 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of ABBV-400 in Combination with Fluorouracil, Leucovorin, and Budigalimab as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic Gas

Clinical Trial Grant
Duke Scholars

Awarded By

AbbVie Inc.

Start Date

November 5, 2024

End Date

October 31, 2029
 

Awarded By

AbbVie Inc.

Start Date

November 5, 2024

End Date

October 31, 2029